Black Diamond Therapeutics to Present at the Jefferies Healthcare Conference
June 02 2023 - 8:00AM
Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage
precision oncology medicine company developing MasterKey therapies
designed to overcome limitations of existing therapies by targeting
families of oncogenic driver mutations in patients with genetically
defined cancers, today announced that its President and Chief
Executive Officer, David M. Epstein, Ph.D., will present an
overview of the Company’s MasterKey programs, including BDTX-1535
and BDTX-4933, at the Jefferies Healthcare Conference on Friday,
June 9, 2023, at 12:45 p.m. ET in New York, NY.
A live webcast of the presentation can be accessed by visiting
the investors relations section of the Company’s website at:
www.blackdiamondtherapeutics.com. A replay of the webcast will also
be available and archived for 90 days following the event.
About Black Diamond
Black Diamond Therapeutics is a clinical-stage precision
oncology medicine company focused on the development of MasterKey
therapies that target families of oncogenic mutations in clinically
validated targets. Black Diamond leverages a deep understanding of
cancer genetics and onco-protein structure and function, to
discover and develop innovative MasterKey therapies. The Company’s
MasterKey therapies are designed to overcome resistance, minimize
on-target, wild-type mediated toxicities, and be brain penetrant to
address significant unmet medical needs of patients with
genetically defined cancers. The Company is advancing a robust
pipeline with lead clinical-stage program BDTX-1535, targeting
MasterKey mutations in both EGFR mutant-positive non-small cell
lung cancer (NSCLC) and in glioblastoma multiforme (GBM), and
BDTX-4933, a program targeting RAF MasterKey mutations in solid
tumors, as well as discovery-stage research programs. The Company’s
proprietary Mutation-Allostery-Pharmacology, or MAP drug discovery
engine, is designed to allow Black Diamond to analyze
population-level genetic sequencing tumor data and validate
MasterKey mutations.
Contact:Julie Seidel, Stern Investor
Relations(212) 362-1200investors@bdtx.commedia@bdtx.com
Black Diamond Therapeutics (NASDAQ:BDTX)
Historical Stock Chart
From Apr 2024 to May 2024
Black Diamond Therapeutics (NASDAQ:BDTX)
Historical Stock Chart
From May 2023 to May 2024